Fludarabine (FLU)
Fludarabine (FLU) is a pharmaceutical drug with 10 clinical trials. Currently 3 active trials ongoing.
Success Metrics
Phase Distribution
Phase Distribution
3
Early Stage
7
Mid Stage
0
Late Stage
Highest Phase Reached
Phase 2Trial Status & Enrollment
0.0%
0 of 0 finished
0.0%
0 ended early
3
trials recruiting
10
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Alpha/Beta TCD HCT in Patients With Inherited BMF Disorders
Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy
QH101 Cell Therapy Relapsed/Refractory(R/R) Acute Myeloid Leukemia(AML) and Myelodysplastic Syndromes(MDS)
Allogeneic CD7 CAR γδ T Cells Therapy Recurrent/Refractory Leukemia
Efficacy and Safety of UCBT With TMI -Based Conditioning Regimen for Adults With Refractory/Relapsed Aplastic Anemia
Clinical Trials (10)
Alpha/Beta TCD HCT in Patients With Inherited BMF Disorders
Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy
QH101 Cell Therapy Relapsed/Refractory(R/R) Acute Myeloid Leukemia(AML) and Myelodysplastic Syndromes(MDS)
Allogeneic CD7 CAR γδ T Cells Therapy Recurrent/Refractory Leukemia
Efficacy and Safety of UCBT With TMI -Based Conditioning Regimen for Adults With Refractory/Relapsed Aplastic Anemia
VEN+DAC+Bu2Flu4 vs Bu2Flu5 Conditioning Regimen for Elderly Myeloid Malignancies Undergoing Allo-HSCT
A Phase I Study of NK042 Cell Injection in Advanced Solid Tumors
G-CSF+DAC+BUCY vs G-CSF+DAC+BF Conditioning Regimen for High-risk MDS Undergoing Allo-HSCT
G-CSF+DAC+BUCY vs G-CSF+DAC+BF Conditioning Regimen for Secondary Acute Myeloid Leukemia Undergoing Allo-HSCT
G-CSF+DAC+BUCY vs G-CSF+DAC+BF Conditioning Regimen for RAEB-1,REAB-2 and AML Secondary to MDS Undergoing Allo-HSCT
All 10 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 10